Uncovering the Right Sequence

Content Outline

Patient Case 1

Standard of Care for High-Risk, Locally Advanced Prostate Cancer

Is Local Treatment Helpful for High-Risk Prostate Cancer?

Confirming Benefit of Local Therapy in High-Risk Prostate Cancer

Treatment Intensification: Can We Improve Outcomes?

Patient Case 1 (cont)

Treatment Options for Non-Metastatic Prostate Cancer After Biochemical Relapse

Importance of Metastasis-Free Survival

Practical Considerations for Treatment Intensity

Toxicity Profiles of Anti-AR Therapies

Quality of Life Impact of AR-Targeted Therapy

Patient Case 1 (cont)

Issues Impacting Treatment Selection for Metastatic CRPC

Immunotherapy Options: Only in the United States

ERA 223 Radium-223 and Abiraterone Acetate and Prednisone in CRPC Patients

Patient Case 2

Defining High-Volume/High-Risk Metastatic Prostate Cancer

Chemotherapy for Metastatic Disease? Risk Status Matters

Updated Results Using First-Line Abiraterone

Local Radiotherapy for Metastatic Disease: STAMPEDE Outcomes Using CHAARTED Disease Volume Definition

High-Risk Patients: Abiraterone or Docetaxel?

Optimal Treatment Selection for Low-Volume Metastatic Disease

Patient Case 2 (cont)

Treatment Sequencing After Progression on First-Line Therapy

Informing Treatment Selection With Genetic Testing

Impact of Bone Health Agents on SSE Risk in ERA 223

Can We Prevent Skeletal Events Associated With Radium Can We Prevent Skeletal Events Associated With Radium? Data From AR Inhibitor Trials

Key Takeaways

Abbreviations

Abbreviations (cont)